Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatomyositis | 3 | 2023 | 30 | 0.930 |
Why?
|
| Fasciitis | 1 | 2024 | 39 | 0.910 |
Why?
|
| Myositis | 3 | 2023 | 86 | 0.880 |
Why?
|
| Arthritis, Juvenile | 4 | 2024 | 58 | 0.850 |
Why?
|
| Eosinophilia | 1 | 2024 | 184 | 0.780 |
Why?
|
| Autoantibodies | 6 | 2023 | 606 | 0.770 |
Why?
|
| Lipodystrophy | 1 | 2021 | 39 | 0.730 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 35 | 0.730 |
Why?
|
| Lung Diseases | 4 | 2023 | 751 | 0.650 |
Why?
|
| Hospitalists | 1 | 2019 | 58 | 0.620 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2019 | 76 | 0.620 |
Why?
|
| Skin Diseases | 1 | 2021 | 371 | 0.580 |
Why?
|
| Skin Ulcer | 2 | 2021 | 76 | 0.580 |
Why?
|
| Hemorrhage | 3 | 2023 | 724 | 0.560 |
Why?
|
| Immunologic Factors | 2 | 2020 | 669 | 0.540 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 100 | 0.540 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2016 | 257 | 0.520 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 255 | 0.520 |
Why?
|
| Hospitals, Pediatric | 1 | 2019 | 796 | 0.470 |
Why?
|
| Immunologic Deficiency Syndromes | 4 | 2021 | 253 | 0.460 |
Why?
|
| Tenosynovitis | 1 | 2014 | 13 | 0.460 |
Why?
|
| Wrist Joint | 1 | 2014 | 34 | 0.460 |
Why?
|
| Ankle Joint | 1 | 2014 | 36 | 0.450 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 477 | 0.450 |
Why?
|
| Polyarteritis Nodosa | 1 | 2012 | 8 | 0.410 |
Why?
|
| Lupus Nephritis | 3 | 2022 | 56 | 0.400 |
Why?
|
| Rituximab | 1 | 2017 | 1594 | 0.400 |
Why?
|
| Vascular Diseases | 1 | 2023 | 234 | 0.380 |
Why?
|
| Child | 20 | 2024 | 30560 | 0.380 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1301 | 0.370 |
Why?
|
| Polymyositis | 1 | 2018 | 13 | 0.310 |
Why?
|
| 5'-Nucleotidase | 1 | 2018 | 63 | 0.290 |
Why?
|
| Acyl Coenzyme A | 1 | 2017 | 31 | 0.290 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 4394 | 0.280 |
Why?
|
| Child, Preschool | 9 | 2024 | 17072 | 0.250 |
Why?
|
| Adolescent | 14 | 2024 | 32689 | 0.240 |
Why?
|
| Interferon Type I | 3 | 2021 | 282 | 0.230 |
Why?
|
| Arthritis | 2 | 2023 | 148 | 0.220 |
Why?
|
| Glomerulonephritis | 1 | 2023 | 109 | 0.210 |
Why?
|
| Lymphadenopathy | 1 | 2023 | 94 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2014 | 7916 | 0.200 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 1016 | 0.190 |
Why?
|
| Hemoptysis | 1 | 2021 | 42 | 0.190 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2021 | 23 | 0.190 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2021 | 13 | 0.190 |
Why?
|
| Coatomer Protein | 2 | 2023 | 33 | 0.190 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2021 | 74 | 0.180 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2021 | 60 | 0.180 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2020 | 8 | 0.180 |
Why?
|
| Methotrexate | 1 | 2024 | 1025 | 0.180 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2020 | 11 | 0.180 |
Why?
|
| Cough | 1 | 2021 | 125 | 0.180 |
Why?
|
| Nephrology | 1 | 2022 | 153 | 0.170 |
Why?
|
| Autoimmune Diseases | 2 | 2020 | 435 | 0.170 |
Why?
|
| Interleukin-18 | 1 | 2020 | 91 | 0.170 |
Why?
|
| Panniculitis | 1 | 2020 | 58 | 0.170 |
Why?
|
| Kidney Diseases | 2 | 2023 | 679 | 0.170 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 1581 | 0.170 |
Why?
|
| Female | 20 | 2024 | 148885 | 0.170 |
Why?
|
| Humans | 29 | 2024 | 270713 | 0.160 |
Why?
|
| Renal Insufficiency | 1 | 2022 | 304 | 0.160 |
Why?
|
| Transition to Adult Care | 1 | 2021 | 118 | 0.160 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 425 | 0.160 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2021 | 216 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2019 | 192 | 0.150 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2018 | 39 | 0.150 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 1436 | 0.150 |
Why?
|
| Fever | 1 | 2021 | 517 | 0.150 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2017 | 17 | 0.150 |
Why?
|
| Male | 17 | 2024 | 128479 | 0.140 |
Why?
|
| Kidney | 3 | 2022 | 2102 | 0.140 |
Why?
|
| Molecular Chaperones | 1 | 2018 | 266 | 0.140 |
Why?
|
| Sjogren's Syndrome | 1 | 1998 | 105 | 0.140 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 4838 | 0.140 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2016 | 13 | 0.140 |
Why?
|
| Immunologic Tests | 1 | 2016 | 35 | 0.140 |
Why?
|
| Infant | 5 | 2022 | 13994 | 0.130 |
Why?
|
| Piperidines | 1 | 2021 | 1099 | 0.120 |
Why?
|
| Aftercare | 1 | 2016 | 250 | 0.120 |
Why?
|
| Neuroblastoma | 1 | 2020 | 706 | 0.120 |
Why?
|
| Symptom Assessment | 1 | 2016 | 271 | 0.110 |
Why?
|
| Age of Onset | 1 | 2016 | 853 | 0.110 |
Why?
|
| Tropomyosin | 1 | 2023 | 34 | 0.110 |
Why?
|
| Gadolinium DTPA | 1 | 2014 | 173 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 4494 | 0.110 |
Why?
|
| Blood Transfusion | 1 | 2016 | 580 | 0.110 |
Why?
|
| Gangrene | 1 | 2012 | 28 | 0.100 |
Why?
|
| Cytoskeletal Proteins | 1 | 2023 | 526 | 0.090 |
Why?
|
| Neoplasms | 1 | 2017 | 15949 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2017 | 2856 | 0.090 |
Why?
|
| Necrosis | 1 | 2012 | 591 | 0.090 |
Why?
|
| Extremities | 1 | 2012 | 311 | 0.090 |
Why?
|
| Cerebrum | 1 | 2010 | 41 | 0.090 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2010 | 17 | 0.090 |
Why?
|
| Adult | 5 | 2024 | 82041 | 0.080 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2010 | 49 | 0.080 |
Why?
|
| Mutation | 2 | 2020 | 15917 | 0.080 |
Why?
|
| Aortitis | 1 | 2008 | 6 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2021 | 3671 | 0.080 |
Why?
|
| Phenotype | 3 | 2018 | 6502 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2023 | 1031 | 0.070 |
Why?
|
| Syndrome | 2 | 2023 | 1409 | 0.070 |
Why?
|
| Contrast Media | 1 | 2014 | 1505 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 5923 | 0.070 |
Why?
|
| Acute Disease | 1 | 2012 | 2492 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2020 | 3561 | 0.070 |
Why?
|
| Brain Diseases | 1 | 2010 | 411 | 0.070 |
Why?
|
| Cerebellum | 1 | 2010 | 467 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 5777 | 0.060 |
Why?
|
| Crohn Disease | 1 | 2008 | 329 | 0.060 |
Why?
|
| Young Adult | 3 | 2022 | 22243 | 0.060 |
Why?
|
| Antibodies, Antinuclear | 1 | 2013 | 50 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 3429 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 7055 | 0.050 |
Why?
|
| Th17 Cells | 1 | 2024 | 162 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2017 | 13419 | 0.050 |
Why?
|
| Interleukin-17 | 1 | 2024 | 251 | 0.050 |
Why?
|
| Microscopic Polyangiitis | 1 | 2021 | 13 | 0.050 |
Why?
|
| Kidney Glomerulus | 1 | 2022 | 148 | 0.050 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2021 | 26 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2023 | 571 | 0.050 |
Why?
|
| Myeloblastin | 1 | 2021 | 65 | 0.050 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2021 | 49 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2024 | 709 | 0.050 |
Why?
|
| Peroxidase | 1 | 2021 | 131 | 0.050 |
Why?
|
| North America | 1 | 2021 | 337 | 0.040 |
Why?
|
| Fibrosis | 1 | 2023 | 715 | 0.040 |
Why?
|
| Personal Autonomy | 1 | 2021 | 210 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 704 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 2021 | 235 | 0.040 |
Why?
|
| Biopsy | 1 | 2007 | 3490 | 0.040 |
Why?
|
| United States | 1 | 2016 | 15828 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2013 | 1824 | 0.040 |
Why?
|
| Motivation | 1 | 2021 | 515 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2018 | 111 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2018 | 233 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 1998 | 134 | 0.040 |
Why?
|
| Mutant Proteins | 1 | 2018 | 233 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2013 | 1186 | 0.040 |
Why?
|
| Urinary Incontinence | 1 | 1998 | 149 | 0.040 |
Why?
|
| Gait | 1 | 1998 | 156 | 0.040 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2018 | 202 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2021 | 9463 | 0.030 |
Why?
|
| Brain | 1 | 2010 | 4202 | 0.030 |
Why?
|
| Vision Disorders | 1 | 1998 | 242 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 4317 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 5048 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2018 | 573 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2023 | 39959 | 0.030 |
Why?
|
| Heterozygote | 1 | 2018 | 1057 | 0.030 |
Why?
|
| Fever of Unknown Origin | 1 | 2015 | 60 | 0.030 |
Why?
|
| Exons | 1 | 2018 | 1388 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 850 | 0.030 |
Why?
|
| Family | 1 | 2018 | 782 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2017 | 610 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 1723 | 0.030 |
Why?
|
| Recurrence | 1 | 2021 | 4878 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 2803 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 3284 | 0.020 |
Why?
|
| Base Sequence | 1 | 2018 | 5405 | 0.020 |
Why?
|
| Cell Line | 1 | 2018 | 5313 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 7787 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 6881 | 0.020 |
Why?
|
| Atrophy | 1 | 2010 | 271 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 3945 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 6766 | 0.020 |
Why?
|
| Inflammation | 1 | 2018 | 2491 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2018 | 6344 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 1127 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 15275 | 0.020 |
Why?
|
| Infliximab | 1 | 2008 | 138 | 0.020 |
Why?
|
| Pulse Therapy, Drug | 1 | 2007 | 11 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2008 | 219 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 6446 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 590 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2017 | 33847 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2007 | 727 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 1436 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8603 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 453 | 0.010 |
Why?
|
| Risk Factors | 1 | 2021 | 17861 | 0.010 |
Why?
|
| Neutrophils | 1 | 2007 | 855 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 3534 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 3245 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 4468 | 0.010 |
Why?
|
| Time Factors | 1 | 2007 | 12978 | 0.010 |
Why?
|